A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting MET and EGFR, in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs LY 3164530 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 07 Jul 2017 Status changed from active, no longer recruiting to completed.
- 07 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.